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Background: Schizophrenia is a severe and enduring disease and is one of the leading
causes of disability worldwide. Cognitive impairment is a core clinical symptom that
plays a crucial role in functional outcomes and prognosis, thus making it a relevant
treatment target. The aim of this study was to assess the efficacy of alpha-7 nicotinic
acetylcholine receptor agonists (α7 nAChR) as adjunctive treatment to enhance cognition
and ameliorate negative symptoms in patients with schizophrenia.
Methods: A search strategy was developed for MEDLINE, Embase, and the Cochrane
Central Register of Controlled Trials up to May 2019. We included randomized controlled
trials (RCTs) that compared antipsychotic treatment plus α7 nAChR agonists with
antipsychotic treatment plus placebo and determined their effects on the main cognitive
domains proposed by the MATRICS initiative and on negative symptoms. Two authors
independently reviewed study eligibility and data extraction and assessed the risk of bias
of the studies included. According to the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) framework, we used a random-effects model
and assessed the quality of the evidence.
Results: Thirteen studies were included in the quantitative analysis. No
differences were found in any of the cognitive domains assessed in four
RCTs (n = 414). In contrast, nine RCTs (n = 978) presented a small effect
in support of α7 nAChR agonists for negative symptoms [standardized mean
difference −0.28, 95% CI (−0.56 to −0.00); P = 0.05], even though the
confidence to support this evidence is low according to the GRADE system.
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Conclusions: Current evidence is too weak to consider α7 nAChR agonists
as an effective add-on treatment to antipsychotics to enhance cognition and
negative symptoms.
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INTRODUCTION
Schizophrenia is a severe and enduring mental disorder and
a worldwide health priority. It is the most prevalent psychotic
disorder, with a global average incidence of 15.2 per 100,000
inhabitants and a male:female ratio of 1.4:1 (1). Schizophrenia
is by far one of the leading causes of disability worldwide,
generating a substantial economic burden, with an annual
estimated cost ranging from US$94 million to US$102 billion
(2). Clinically, schizophrenia is characterized by a heterogeneous
range of symptoms classified under the following domains:
positive symptoms (e.g., delusions and hallucinations), negative
symptoms (e.g., affective flattening, alogia, apathy, and social
isolation), cognitive deficits (e.g., speed of processing and
attention deficits), and affective symptoms (e.g., hypothymia,
mania, and anxiety) (3).
Most antipsychotic agents have demonstrated efficacy in
improving positive symptoms; however, data on their efficacy
in negative symptoms and cognitive deficits are limited (4–
6). Cognitive deficits are considered one of the most disabling
symptoms and are considered one of the best predictors
of long-term functional disability (7–10). Such recognition
has been the main promoter for the development of new
therapeutic approaches under the premise that improving
cognitive impairments can indirectly result in improvements in
patients’ psychosocial functioning (11, 12). As a consequence,
cognition has become a priority treatment target.
The two main approaches that have been developed are
the psychosocial approach, which is based mainly on cognitive
rehabilitation programs, and the pharmacological approach,
which is based on the development of cognitive enhancers
evaluated under the Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) initiative.
Among the potential pharmacological therapeutic targets for
developing cognitive enhancers, the MATRICS initiative has
stressed the importance of the cholinergic system (13). This
pathway has been widely associated with the modulation of
cognitive processes (e.g., attention and memory) in healthy
people. Donepezil and galantamine, which delay cognitive
impairment in the earlier stages of Alzheimer’s disease by acting
on the cholinergic system (14), were among the first cognitive
enhancers studied in schizophrenia. Nevertheless, a recent meta-
analysis analyzing the efficacy of acetylcholinesterase inhibitors
for cognitive deficits in schizophrenia has shown inconclusive
results (15).
During the last decade, nicotinic acetylcholine receptors
(nAChR) have been identified as a promising new therapeutic
target. Specifically, the nicotinic subtype alpha-7 has been
proposed as a potential target for the pharmacological treatment
of neurocognitive impairment (16). Although evidence on the
efficacy of nicotinic acetylcholine agonists is based on preclinical
research (17), some preliminary clinical evidence has shown
promising results. Postmortem studies have revealed reduced
availability of α7 binding receptors (17) and reduced α7
expression in specific brain regions in schizophrenia, e.g., the
hippocampus and frontal cortex (18). Studies addressing the
presence of impairments in sensory gating report a decreased
ability to gate auditory and eye-tracking stimuli, primarily due to
alteration of chromosome 15 (18). Given that this chromosome
contains the CHRNA7 gene, which encodes the α7 nAChR
(18), such results seem to suggest the presence of an impaired
cholinergic neurotransmission signal (19, 20). Various clinical
studies have described the positive influence of nicotine in
diverse cognitive domains of patients with schizophrenia, such
as attention and working memory processes (21–23). Hence,
pharmacological compounds targeting nicotinic receptors have
been considered potentially useful in the treatment of these
deficits. More specifically, pharmacological treatment targeting
the α7 nAChR is as a promising option that can enhance
cognitive processes and ameliorate negative symptoms (24).
Recent trials have tried to prove the procognitive effect of
new compounds targeting the α7 nAChR as add-on treatment
to antipsychotic regimens, and in recent years, the several
compounds identified as α7 nAChR agonists include RG3487,
TC-5619, ABT-126, DMXB-A, and tropisetron. Despite the
promising results for α7 nAChR agonists, evidence for their
efficacy as procognitive drugs remains inconclusive (25). This
study aims to summarize evidence on the efficacy of α7
nAChR agonists vs. placebo when used as adjunctive treatment




Articles were included if they fulfilled the following conditions:
a) Inclusion of patients diagnosed with schizophrenia or
schizophreniform, schizoaffective, delusional, or psychotic
disorder not otherwise specified according to the diagnostic
criteria of the Diagnostic and Statistical Manual of Mental
Disorders (DSM) (DSM-III-R, DSM-IV-R, or DSM-V) (3)
or the International Classification of Mental Diseases (ICD)
(ICD-9 or ICD-10) (26).
b) Randomized placebo-controlled or double-blind clinical
trials, open-label studies, or crossover studies. We excluded
case series, observational designs, and studies with an
n= 1 design. We compared cognitive enhancers as add-on
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treatments with add-on placebo to detect possible effects.
If an effect existed and was clinically relevant, we extended
the comparison to include several cognitive enhancers as
competitive treatments.
No language restrictions were imposed in the choice of articles.
Participants and Interventions
We included trials with patients diagnosed with schizophrenia
or a schizophreniform, schizoaffective, delusional, or psychotic
disorder not otherwise specified, according to DSM (3) or ICD
(26) criteria. Patients had to be clinically stable and treated
with typical or atypical antipsychotic agents. Experimental
interventions were α7 nAChR as adjunctive medication to
antipsychotic treatment. We included α7 nAChR agonists
irrespective of the duration of treatment and the doses. The
comparator intervention was matching placebo as adjunctive
medication to antipsychotic treatment.
Outcomes
Primary Outcome—Cognitive Domains
We assessed efficacy according to the results of cognitive
tests and batteries based on the main cognitive domains
affected in schizophrenia proposed by the MATRICS initiative:
attention/vigilance, speed of processing, working memory, verbal
learning, visual learning, problem solving, and social cognition
(7). For each domain, we selected those psychometric measures
that were replicated across trials or considered representative of a
specific domain. For this purpose, we used the systematic review
of Bakkour et al. (27) and the monograph of Lezak et al. (28) as
general guidelines to identify and categorize the main cognitive
domains evaluated through each cognitive test. Table 1 illustrates
the main cognitive tests and batteries included clustered under
the main domains proposed by the MATRICS initiative (7).
Secondary Outcome—Negative Symptoms
For the assessment of negative symptoms, we considered those
studies that used standardized instruments to evaluate negative
clinical symptoms such as the Negative Symptoms Assessment
Scale (NSA-16) (42), the Positive and Negative Syndrome Scale
for Schizophrenia (PANSS) (43), and the Scale for Negative
Symptoms Assessment (SANS) (Table 1) (44).
Search Methods for the Identification of
Studies
A search strategy was developed to identify potential studies (see
search strategy in Supplementary Appendix 1). We developed
a search strategy for MEDLINE (Ovid), Embase (Ovid), and
the Cochrane Central Register of Controlled Trials (CENTRAL)
and searched for RCTs up to May 2019. We performed the
search without language or date restrictions. The references of
potentially eligible trials and relevant reviews were searched for
additional citations.
Data Extraction and Analysis
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement to design
the search flowchart. After removing duplicate records, two
independent and blinded review authors (JB, MR) screened the
titles and abstracts of the studies obtained from the literature
searches to assess eligibility. We obtained full reports from the
studies considered to be potentially eligible. Disagreements were
resolved by discussion and consensus.
The data extracted included the following: primary and
secondary outcomes, number of patients included, population
characteristics (including age, sex, duration of illness, and
diagnosis), smoking status, duration of treatment, outcome scales
used, and tests for cognitive and negative assessment (i.e.,
mean, standard deviation). In case of missing outcome data, the
corresponding author of the study was contacted via email.
The study characteristics and quantitative data were extracted
using a data extraction sheet form. Sample sizes, means, and
standard deviations from each intervention were obtained for
each relevant outcome to calculate standardizedmean differences
(SMDs). We applied SMDs owing to the different measures,
clinical tests, and metrics used to assess cognitive deficits
and negative symptoms. We interpreted SMDs as small effect,
medium effect, or large effect according to Cohen’s criteria, with
0.2 representing a small effect, 0.5 a moderate effect, and 0.8 a
large effect (45).
After a training exercise, two independent authors (JB, MR)
assessed the risk of bias for each trial included to determine study
quality according to the PRISMA guidelines and the Cochrane
Handbook of Systematic Reviews of Interventions (46). Risk of
bias was classified as low, unclear, or high. Disagreements were
resolved by discussion and consensus. We used a random-effects
model to combine individual effect sizes (47).
We used the I2 statistic to assess the heterogeneity of the
studies. The I2 statistic quantifies inconsistencies between the
studies. We considered I2-values >60% as indicating substantial
heterogeneity and conducted a subgroup analysis if feasible
to explain possible sources of heterogeneity. All analyses were
performed using R (https://cran.r-project-org/), specifically the
packages “meta” and “metaphor” (48, 49).
Finally, we assessed reporting bias depending on the
availability of the study protocols described in the methodology
section of each trial. The overall quality of evidence for each
cognitive and negative measure was presented according to the
Grading of Recommendations Assessment, Development, and
Evaluation (GRADE) approach (50). We judged the quality
of evidence considering the following dimensions: (a) study
limitations (risk of bias across the studies at the outcome level),
(b) inconsistency, (c) imprecision, (d) indirectness, and (e)
publication bias. Two review authors (JB, MR) independently
rated the quality of evidence for each outcome as high, moderate,
low, or very low according to the GRADE framework (50). To
generate an evidence table for each comparison, we used the
online Guideline Development Tool (https://gradepro.org).
RESULTS
Characteristics of the Studies Included and
Patients
Our search identified 393 articles. After excluding duplicates, 254
references were reviewed by title and abstract, and 15 studies were
considered eligible and assessed as full text; of these, 13 studies












































TABLE 1 | Characteristics of the studies included in the systematic review and meta-analysis of cognitive deficits and negative symptoms in schizophrenia.
Trial name RCT design
follow-up





Outpatients; 9 women, 22 men; age range 22–60.
DSM-IV-TR diagnosis of schizophrenia with stable
symptoms, treated with a stable dose of typical or
atypical antipsychotics. Exclusion criteria:
substance abuse, smoking in the previous month,
and women of fertile age
DMXB-A (75 or 150 mg/day) plus typical or
atypical antipsychotic treatment vs.
placebo plus typical or atypical
antipsychotic treatment
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP




Reasoning/problem solving: NAB: Mazes
Social cognition: MSCEIT
Scale for the Assessment
of Negative Symptoms
(SANS)
Haig et al. (30) Parallel
12 weeks
Outpatients; 72 women, 131 men; age range
22–60. DSM-IV-TR diagnosis of schizophrenia
confirmed by the 6.0 Mini International
Neuropsychiatric Interview with stable symptoms,
treated with a stable dose of an atypical
antipsychotic. Exclusion criteria: substance abuse,
treatment with clozapine, tricyclic antidepressants,
or monoamine oxidases (MAOs)
ABT-126 (10 or 25 mg/day) plus atypical
antipsychotic vs. placebo plus atypical
antipsychotic treatment
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP








Haig et al. (31) Parallel
12 weeks
Outpatients; 171 women, 190 men; age range
20–65. DSM-IV-TR diagnosis of schizophrenia with
stable symptoms, treated with a stable dose of
atypical antipsychotics. Exclusion criteria:
substance abuse, treatment with mood stabilizers,
tricyclic antidepressants, MAOs, and patients with
doses >100 mg/day of clozapine
ABT-126 (25, 50, or 75 mg/day) plus typical
or atypical antipsychotic treatment vs.
placebo plus typical or atypical
antipsychotic treatment
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP








Haig et al. (32) Parallel
12 weeks
Outpatients; 32 women, 121 men; age range
22–60. DSM-IV-TR diagnosis of schizophrenia
confirmed by the 6.0 Mini International
Neuropsychiatric Interview with stable symptoms,
treated with a stable dose of atypical
antipsychotics. Exclusion criteria: substance
abuse, treatment with mood stabilizers, tricyclic
antidepressants, MAOs, and patients with doses
>100 mg/day of clozapine
ABT-126 (25 or 75 mg/day) plus atypical
antipsychotic treatment vs. placebo plus
antipsychotic treatment
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP








Keefe et al. (33) Parallel
12 weeks
Outpatients; 102 women, 215 men; age range
20–55. DSM-IV-TR diagnosis of schizophrenia or
schizoaffective disorder with stable symptoms,
treated with
Encenicline (0.27 or 0.9 mg/day) plus
atypical antipsychotic treatment vs. placebo
plus atypical antipsychotic treatment
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP





























































































TABLE 1 | Continued
Trial name RCT design
follow-up
Population Interventions Cognitive domains Negative symptoms
a stable dose of atypical antipsychotics. Exclusion
criteria: treatment with clozapine, antipsychotic




Reasoning/problem solving: NAB: Mazes
Social cognition: MSCEIT
Kem et al. (34) Parallel
4 weeks
Outpatients; 20 women, 60 men; age range
18–60. DSM-IV diagnosis of schizophrenia with
stable symptoms, treated with a stable dose of
typical or atypical antipsychotics. Exclusion criteria:
substance abuse and treatment with clozapine
DMXB-A-ER 150 mg/day plus typical or
atypical antipsychotic drugs vs. placebo
plus typical or atypical antipsychotic drugs
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP




Reasoning/problem solving: NAB: Mazes
Social cognition: MSCEIT







Outpatients; 57 women, 128 men; age range
16–60. DSM-IV diagnosis of schizophrenia with
stable symptoms, treated with a stable dose of
quetiapine or risperidone
TC-5619 (in increasing doses up to 25
mg/day) plus quetiapine or risperidone vs.
placebo plus quetiapine or risperidone
CogState Battery
Speed of processing: detection test
Attention: identification test
Working memory: one-back test and two-back test
Verbal learning: International Shopping List Test
Visual learning: Continuous Paired Associate
Learning Test and One Card Learning Test
Reasoning/problem solving: Groton Maze Learning
Test and set-shifting test
Social cognition: social–emotional test
Positive and Negative
Syndrome Scale (PANSS)
Olincy et al. (36) Parallel
1 day
Outpatients; 4 women, 8 men; age range 20–58.
DSM-IV diagnosis of schizophrenia with stable
symptoms, treated with a stable dose of typical or
atypical antipsychotics
DMXB-A (75 mg/day plus 37.5 mg/day or
150 mg/day plus 75 mg/day) plus typical or
atypical antipsychotic drugs vs. placebo
plus typical or atypical antipsychotic drugs
RBANS
Attention: digit span and coding
Immediate memory: list learning and memory story
Delayed memory: list recall, list recognition, story
recall, and figure recall
Visuospatial/construction: figure copy and line
orientation






Outpatients; 6 women, 15 men; age range 18–55.
DSM-IV diagnosis of schizophrenia with stable
symptoms, treated with a stable dose of
aripiprazole, olanzapine, paliperidone, or
risperidone
EVP-6124 (0.3 or 1.0 mg/day) plus
aripiprazole, olanzapine, paliperidone, or
risperidone vs. placebo plus aripiprazole,
olanzapine, paliperidone, or risperidone
CogState Battery
Speed of processing: detection test
Attention: identification test
Working memory: one-back test and two-back test
Verbal learning: International Shopping List Test
Visual learning: Continuous Paired Associate
Learning Test and One Card Learning Test
Reasoning/problem solving: Groton Maze Learning
Test and set-shifting test




























































































TABLE 1 | Continued
Trial name RCT design
follow-up
Population Interventions Cognitive domains Negative symptoms
Shinna et al. (38) Parallel
8 weeks
Outpatients; 21 women, 19 men; age range
21–48. DSM-IV-TR diagnosis of schizophrenia with
stable symptoms, treated with a stable dose of
risperidone (2–6 mg/day). Exclusion criteria:
substance abuse
Tropisetron 10 mg/day plus risperidone (2
to 6 mg/day) vs. placebo plus risperidone
(2 to 6 mg/day)
CANTAB
Speed of processing: simple and 5-choice (RTI)
Attention: rapid visual information processing (RVP)
Working memory: spatial working memory (SWM)
Verbal learning: verbal recognition-recall memory
(VRM)
Visual learning: Paired Associate Learning (PAL)
Reasoning/problem solving: Intra/Extradimensional
Set Shifting and One Touch Stockings of
Cambridge (OTS)







Outpatients; 66 women, 149 men; age range
15–55. DSM-IV-TR diagnosis of schizophrenia with
stable symptoms, treated with a stable dose of
risperidone (2–6 mg/day). Exclusion criteria:
substance abuse
RG3487 (5, 10, or 15 mg/day) plus
risperidone (2–6 mg/day) vs. placebo plus
risperidone (2–6 mg/day)
MATRICS (MCCB)
Speed of processing: BACS symbol coding, animal
naming, TMT-A
Attention: CPT-IP








Walling et al. (40) Parallel
24 weeks
Outpatients; 180 women, 297 men. DSM-IV-TR
diagnosis of schizophrenia with stable symptoms
treated with a stable dose of atypical
antipsychotics. Exclusion criteria: substance abuse,
treatment with clozapine, sertindole, melperone,
mood stabilizers, antidepressants, or anxiolytics
TC-5619 (5 or 50 mg/day) plus atypical
antipsychotic vs. placebo plus atypical
antipsychotic treatment
CogState Battery
Speed of processing: detection test
Attention: identification test
Working memory: one-back test and two-back test
Verbal learning: International Shopping List Test
Visual learning: Continuous Paired Associate
Learning Test and One Card Learning Test
Reasoning/problem solving: Groton Maze Learning
Test and set-shifting test
Positive and Negative
Syndrome Scale (PANSS)
Zhang et al. (41) Parallel
10 days
Inpatients; 10 women, 30 men; age range 20–55.
DSM-IV-TR diagnosis of schizophrenia with stable
symptoms, treated with a stable dose of
risperidone (3–6 mg/day). Exclusion criteria:
substance abuse and presence of a comorbid
mood or anxiety disorder
Tropisetron (5, 10, or 20 mg/day) plus
risperidone (3–6 mg/day) vs. placebo plus
risperidone (3–6 mg/day)
RBANS
Attention: digit span and coding
Immediate memory: list learning and memory story
Delayed memory: list recall, list recognition, story
recall, and figure recall
Visuospatial/construction: figure copy and line
orientation
Language: picture naming and semantic fluency
Not assessed
MCCB, MATRICS Consensus Cognitive Battery; BACS, Brief Assessment of Cognition in Schizophrenia; TMT-A, Trail Making Test Part A; CPT-IP, The Continuous Performance Test-Identical Pairs version; WMS-III, Wechsler Memory
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FIGURE 1 | Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram.
were included in the present review. Four studies were included
in the quantitative analysis for cognitive outcomes and nine
studies were included in the quantitative analysis for negative
symptoms (Figure 1).
Thirteen studies compared the effectiveness of antipsychotics
plus α7 nAChR agonists with antipsychotics plus placebo
for treatment of cognitive deficits. Of these, three studies
used ABT-126 (30–32) or DMXB-A (29, 34, 36), two
studies used TC-5619 (35, 40) or tropisetron (38, 41),
and one study used encenicline (33), EVP-6124 (37),
or RG 3487 (39).
To assess the effectiveness of antipsychotics plus α7 nAChR
agonists vs. placebo in negative symptoms, we finally included for
analysis three studies using ABT-126 (30–32), two studies using
tropisetron (38, 51) or DMXB-A (29, 34), and one study using
RG 3487 (39) or citicoline (52) (Table 1). The sample size of the
studies ranged from 12 to 477 participants, with a median of 153
participants (IQR 40 to 215).
Risk of Bias of the Studies Included in the
Qualitative Synthesis
The overall risk of bias across the studies is presented in
Figure 2. Except for two studies (29, 41), all studies were
reported as randomized and provided appropriate information
to assess the randomization sequence procedure. Overall, the
risk of bias of random sequence generation was rated as
low. Five studies (29, 33, 39, 41, 52) presented an unclear
risk for allocation concealment. Overall, the risk of bias of
allocation concealment was rated as unclear. All studies reported
appropriate information for blinding conditions regarding
participants and personnel and outcome assessment. The risk
of bias for blinding participants, personnel, and assessors was
rated as low for all outcomes. One study presented an unclear
risk for incomplete data outcomes (29), since it did not provide
data on loss or withdrawal of patients. The study by Haig et al.
(31) was rated as having a high risk of bias, since when losses
in treatment were described, differences were observed between
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FIGURE 2 | Risk of bias summary of included studies.
the treatment arms or between the interventions. Overall, the
risk of bias for incomplete outcome data was rated low for all
outcomes. As for selective reporting, all the studies reported on
clinical trial registration. However, one study (33) was reported
as having an unclear risk for selective reporting due to primary
and secondary outcome-specific variables that were not provided
in the clinical trial protocol. We also considered that Freedman
et al. (29) presented a high risk of bias because the variables and
measures reported in the registered clinical trial protocol did not
coincide with those presented in full-text articles. Finally, except
for the studies carried out by Zhang et al. (41) and Nozoorian
et al. (51), all the other studies included in the qualitative analysis
presented a strong suspicion of publication bias owing to the
direct participation of the pharmaceutical industry.
Effects of Interventions
A summary of the main findings is presented in Figure 3.
Primary Outcome—Cognitive Deficits
Speed of Processing
Based on all available evidence (three studies, including 376
randomized participants: 268 on α7 nAChR agonists, 108 on
placebo), and given the low quality of evidence, adding α7
agonists to antipsychotic treatment has little or no effect on
speed of processing. SMDs are compatible with small tomoderate
effects, supporting either α7 agonists or placebo (SMD −0.02,
95% CI−0.24 to 0.20; P = 0.86) (Figure 3). Effect estimates were
not statistically heterogeneous (χ2 = 1.22 on 2 df, P = 0.54, I2 =
0%). We downgraded the quality of evidence owing to a strong
suspicion of publication bias.
Attention
Based on three studies including 413 randomized participants
(296 on α7 nAChR agonists, 117 on placebo) and providing low-
quality evidence, adding α7 agonists to antipsychotic treatment
may have little or no effect on attention. SMD values showed a
compatible small to moderate effect supporting either α7 agonists
or placebo (SMD −0.09, 95% CI −0.37 to 0.02, P = 0.56)
(Figure 3). Heterogeneity in effect estimates was low (χ2 = 4.51
on 3 df, P = 0.21, I2 = 34%). We downgraded the quality of
evidence owing to a strong suspicion of publication bias.
Working Memory
Based on three studies, including 380 randomized participants
(268 on α7 nAChR agonists, 112 on placebo) and providing
low-quality evidence, adding α7 agonists to antipsychotic
treatment may have little or no effect on working memory.
The SMD showed a small to moderate effect supporting either
α7 agonists or placebo (SMD 0.00, 95% CI −0.23 to 0.22,
P = 0.97) (Figure 3). Effect estimates were not statistically
heterogeneous (χ2 = 0.42 on 2 df, P = 0.81, I2 = 0%). We
downgraded the quality of evidence owing to a strong suspicion
of publication bias.
Verbal Learning
Based on four studies including 414 randomized participants
(296 on α7 nAChR agonists, 118 on placebo) and providing low-
quality of evidence, adding α7 agonists antipsychotic treatment
had little or no effect on verbal learning. SMD values are
compatible with a small tomoderate effect supporting α7 agonists
and moderate effects supporting placebo (SMD −0.11, 95%
CI −0.47 to 0.25, P = 0.55) (Figure 3). Effect estimates were
moderately heterogeneous (χ2 = 6.72 on 3 df, P = 0.08, I2 =
55%). We downgraded the quality of evidence owing to a strong
suspicion of publication bias.
Visual Learning
Based on four studies, including 414 randomized participants
(296 on α7 nAChR agonists, 118 on placebo) and providing low-
quality evidence, adding α7 agonists to antipsychotic treatment
may have little or no effect on visual learning. SMD values are
compatible with a small tomoderate effect supporting α7 agonists
and a very small effect supporting placebo (SMD 0.12, 95% CI
−0.09 to 0.34, P = 0.26) (Figure 3). Effect estimates were not
statistically heterogeneous (χ2 = 2.22 on 3 df, P = 0.53, I2 =
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FIGURE 3 | Overall efficacy by cognitive domain of antipsychotic drug plus α-7 nAChR agonists vs. antipsychotic drug plus placebo.
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FIGURE 4 | Overall efficacy in negative symptomatology of antipsychotic drug plus α-7 nAChR agonists vs. antipsychotic drug plus placebo.
0%). We downgraded the quality of evidence owing to a strong
suspicion of publication bias.
Problem Solving
Based on three studies, including 376 randomized participants
(268 on α7 nAChR agonists, 108 on placebo) and providing low-
quality evidence, adding α7 agonists to antipsychotic treatment
may have little or no effect on reasoning/problem solving. The
SMD values are compatible with a very small effect supporting α7
agonists and a moderate effect supporting placebo (SMD −0.14,
95% CI−0.36 to 0.08, P = 0.22) (Figure 3). Effect estimates were
not statistically heterogeneous (χ2 = 0.28 on 2 df, P = 0.87, I2 =
0%). We downgraded the quality of evidence owing to a strong
suspicion of publication bias.
Social Cognition
Based on two studies including 345 randomized participants
(248 on α7 nAChR agonists, 97 on placebo) and providing low-
quality evidence, α7 agonists have little or no effect on problem
solving. The SMD values are compatible with a minimal effect
supporting α7 agonists and a moderate effect supporting placebo
(SMD −0.15, 95% CI −0.39 to 0.08, P = 0.20) (Figure 3). Effect
estimates were not statistically heterogeneous (χ2 = 0.62 on 1
df, P = 0.43, I2 = 0%). We downgraded the quality of evidence
owing to a strong suspicion of publication bias.
Secondary Outcome—Negative Symptoms
Based on nine studies including 978 randomized participants
(600 on α7 nAChR agonists, 378 on placebo) and providing low-
quality evidence, adding α7 agonists to antipsychotic treatment
may have a low to moderate effect on negative symptoms. The
SMD values are compatible with a moderate effect supporting α7
agonists over placebo (SMD −0.28, 95% CI −0.56 to −0.00, P =
0.05) (Figure 4). Effect estimates were statistically heterogeneous
(χ2 = 29.79 on 8 df, P < 0.001, I2 = 73%). Considering such
heterogeneity, we observed that the study of Noroozian et al. (51)
had a major impact on overall heterogeneity and effect size. Its
removal from the evidence set decreased I2 from 73 to 55% and
the SMD to−0.15 (95% CI−0.39, 0.08). Whereas, heterogeneity
between effects across studies decreased, the SMD also decreased
from −0.28 to −0.15. We downgraded the quality of evidence
owing to a strong suspicion of publication bias and unexplained
heterogeneity (inconsistency).
DISCUSSION
This systematic review and meta-analysis examined the efficacy
of adding α7 nAChR agonists to antipsychotic treatment in
cognitive deficits and negative symptoms in patients diagnosed
with a schizophrenia spectrum disorder. Overall, α7 agonists
may be more efficacious than placebo, even though the quality
of evidence remains low owing to uncertainty over the quality
of evidence.
Our main finding was that there was no general effect of α7
nAChR agonists as adjunctive treatment on cognitive deficits.
Our results support the view that adding α7 nAChR agonists
to habitual antipsychotic medication has little or no effect on
any of the cognitive domains evaluated. We downgraded the
quality of evidence to low quality in all of the cognitive domains
assessed owing to suspected publication bias. Consistent with
our results, a 2017 systematic review and meta-analysis (53)
analyzing the effect of α7 and α4β2 receptor agonists in patients
with schizophrenia did not reveal an overall improvement in
cognitive (or negative) outcomes when measuring composite
cognitive scores. Moreover, in this study, the individual cognitive
domains typically affected in these patients were not taken into
consideration separately.
We did not evaluate the effect of α7 nAChR agonists on
overall cognitive function, as we do not consider that a composite
neurocognitive measure is a valid representative measure for the
evaluation of the real cognitive effects of a specific treatment.
Thus, we avoided this problem by evaluating the main cognitive
domains proposed by the MATRICS initiative (7) to estimate
the effect of these treatments on cognitive functioning. Our
view is that the assessment of individual cognitive domains is
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essential for estimating the actual effect of those treatments on the
cognitive areas that are prototypically affected in schizophrenia.
Besides, this approach is of particular importance in the social
cognition domain, as the effect observed has been shown to be
strongly correlated with the daily functioning of schizophrenia
patients (54, 55).
There was no evidence of heterogeneity in any specific
cognitive domain (I2 < 60%). As mentioned previously, evidence
of reporting bias was suspected for all cognitive domains, owing
to partial presentation of raw data for specific cognitive domains.
Reporting of data in both full-text format and as supplemental
material was deficient in most studies, except the four studies
included in the quantitative analysis (29, 33, 39, 41).
Regarding negative symptoms, α7 nAChR agonists do present
moderate effects as adjunctive treatment on negative symptoms.
Although there was considerable heterogeneity among the
studies reporting negative symptoms (I2 = 73%), this situation
does not seem to be accounted for by other clinical moderators.
For that reason, we did not perform a subgroup analysis. We
did indeed influence analyses by removing one study at a time
from the evidence set. As presented in the results section,
the residual heterogeneity observed after removing the study
of Noroozian et al. (51) could be explained using a random-
effects analysis model, in which it is considered that the studies
included are a random sample of the population of all studies
and are weighted. Finally, we downgraded the quality of evidence
because of a strong suspicion of publication bias with respect to
negative symptoms.
Only four of 13 studies complied with the CONSORT
guidelines for reporting clinical trials and presented raw data
to assess the efficacy of α7 nAChR agonists on cognitive
deficits. It is remarkable that even though cognition was
considered the primary measure in most of the studies
included, the completeness of information was greater for
clinical outcomes, with a total of nine trials providing either
full-text data or Supplementary Material for the assessment
of negative symptoms. Transparency and completeness in
reporting biomedical research are essential when evaluating
the methodological quality and reproducibility of clinical trials.
Despite the development of the CONSORT statement in 2010
to provide an evidence-based checklist of recommendations
for reporting the findings of randomized clinical trials, a large
proportion of biomedical trials do not yet provide sufficiently
high-quality reporting.
Most of the clinical trials included in this review did not
report a duration of treatment beyond 12 weeks, except for that
of Walling et al. (40), where follow-up was longer than the
average and data were analyzed at weeks 12 and 24. Moreover,
and from a clinical point of view, it is interesting to consider the
potential effect of these prognostic drugs on patients’ day-to-day
functionality. While evidence has shown that improvements in
cognitive functioning correlate with actual patient functioning,
recommendations from institutions, such as the FDA-NIMH,
have highlighted the need to include variables that assess the
impact on patient functionality as co-primary measures (56).
Despite this, only six studies considered the inclusion ofmeasures
to assess patients’ functional capacity.
It is also necessary to consider that patients included in most
clinical trials may not be representative of daily clinical practice,
as inclusion criteria are often very restrictive (e.g., chronically
ill patients with stable symptoms, higher rates of adherence, or
patients not presenting another psychiatric comorbidity, such
as substance abuse or dependence). Implementation of such
strategies in daily clinical practice could be limited. Overall, the
quality of evidence is low, suggesting that prescribing α7 nAChR
agonists as adjunctive therapy does not seem to improve the
prototypical clinical deficits of schizophrenia, such as negative
and cognitive symptoms.
Limitations
Our work is subject to a series of limitations.
First, we could not include some studies because the authors
did not provide enough data, either as full text or Supplementary
Material. In addition, most studies did not present appropriate
information in the methods section to assess the risk of bias in
the study and outcomes. None of the authors we contacted to
obtain supplementary information and data for cognitive and
negative measures responded to our requests. For this reason, the
quantitative analysis for cognitive outcomes includes a very small
number of studies.
The large number of cognitive tasks and batteries widely used
in the literature to evaluate cognitive deficits in patients with
schizophrenia made assessment of the intervention effects of a
specific treatment over the years challenging. Additionally, while
studies frequently report combined or pooled cognitive measures
as a standard general measure of real cognitive functioning,
composite measures are difficult to understand and interpret.
Given this heterogeneity, the MATRICS initiative emerged
to provide unified reporting criteria for the main cognitive
processes affected in schizophrenia (7). Even if the MATRICS
initiative is subject to methodological and clinical criticisms, it
has made it possible to frame cognitive constructs and select
standardized cognitive measures to assess cognitive functions.
The average duration of clinical trials is short. In general
terms, clinical trials evaluating the effectiveness of cognitive
enhancers in schizophrenia are shorter than 12 weeks. As stated
by Green et al. (54), the desirable effects on cognition, and even
more so on the patient’s functioning, can be expected over a
period of 6 to 12 months. As a result, the studies included may
not have been sufficiently long to provide a genuine assessment
of the long-term efficacy and safety of cognitive enhancers (54).
Since a wide range of cognitive alterations are present prior
to the onset of the disease and these follow a stable course
(57, 58), it is necessary to consider the inclusion of patients
with a first psychotic episode. The inclusion of this group could
help us to understand and evaluate those treatments in more
recently diagnosed patients and, with it, prevent resistance to
pharmacological treatment.
Conclusions
To summarize, we found no evidence of the effectiveness
of α7 nAChR as add-on treatment for cognitive deficits in
schizophrenia. Although there is a small effect supporting the use
of α7 nAChR agonists for negative symptoms, the general quality
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of evidence is low. To provide a more accurate picture of the
actual effects of such treatments, we need adequately powered
clinical trials, as well as a preregistration and/or clear reporting
of methods and outcomes in accessible protocols, in order to
prevent both reporting bias and publication bias.
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